Litcius/Paper detail

Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non–muscle-invasive bladder cancer after BCG failure

Rodolfo Hurle, Roberto Contieri, Paolo Casale, Emanuela Morenghi, Alberto Saita, Nicolò Maria Buffi, Giovanni Lughezzani, Piergiuseppe Colombo, Nicola Frego, Vittorio Fasulo, Marco Paciotti, Giorgio Guazzoni, Massimo Lazzeri

2020Urologic Oncology Seminars and Original Investigations26 citationsDOI

Topics & Concepts

MedicineGemcitabineBladder cancerCystoscopyUrologyCystectomyConfidence intervalCarcinoma in situSurgeryInternal medicineUrinary systemCancerBladder and Urothelial Cancer TreatmentsImmune responses and vaccinationsUrinary and Genital Oncology Studies
Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non–muscle-invasive bladder cancer after BCG failure | Litcius